Anastrozole preferred to tamoxifen for treatment of early-stage breast cancer
This article has no abstract so we have provided the first paragraph of the full text.
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial concluded that anastrozole was more effective than tamoxifen in preventing recurrence of breast cancer. The ATAC Trialists' Group recently reported results from a detailed analysis of the safety and tolerability of the two compounds and combined these data with efficacy outcomes to produce overall risk–benefit indices. The researchers found that anastrozole was better tolerated, produced fewer adverse events, had a superior risk–benefit profile and was associated with a lower breast cancer recurrence rate than tamoxifen.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.